BILLERICA, Mass. — Lucent Diagnostics, a brand of Quanterix Corporation, announced a partnership with Life Line Screening aimed at expanding nationwide access to non-invasive, blood-based biomarker testing in community settings.
Under the collaboration, Life Line Screening will offer Lucent’s blood-based diagnostic test across its national network, with programs already underway in Florida, California and Texas. The companies said the partnership is designed to improve access to early detection tools for chronic conditions by delivering testing outside traditional clinical environments.
According to the Alzheimer’s Association, an estimated 7 million Americans are currently living with Alzheimer’s disease, while another 6 million to 7 million are experiencing symptoms of Mild Cognitive Impairment. The companies said those figures highlight the need for scalable testing approaches that can help identify disease earlier, when intervention may be more effective.
“Too many chronic conditions go undetected until they become life-altering events,” said Jim Waters, Chief Operating Officer at LLS. “By partnering with Lucent Diagnostics, we’re able to continue to expand our mission of uncovering asymptomatic risks earlier and more equitably. This partnership has the potential to impact numerous lives by supporting more informed treatment pathways, and it’s something we’re excited to bring to communities across the country.”
Life Line Screening operates a mobile delivery model, offering testing in community-based venues such as community centers, churches and senior centers. Test results can then be shared with primary care physicians to support early intervention and proactive lifestyle management.
“Scientific rigor shouldn’t stop at the laboratory door. Through LLS, Lucent Diagnostics is bringing validated, high-quality science into community testing networks, helping ensure that everyone has access to information for use by their physician and not only in a research setting. This is a critical step toward earlier, more reliable detection of Alzheimer’s Disease,” said Zachary Fernandes, Quanterix General Manager for Lucent Diagnostics.
The companies said the partnership aligns with their shared goal of providing accessible, non-invasive testing options to the general public to help identify potential disease markers earlier in the care continuum.
